Biocare Medical Finalizes Acquisition of CymoGen Dx

Biocare Medical, LLC is pleased to announce that the acquisition of New Windsor, NY based CymoGen Dx, LLC has been finalized. “We are very excited to be adding the portfolio of FISH [Fluorescent in situ Hybridization] probes from CymoGen Dx to our ever-expanding offerings in the Molecular Diagnostic arena,” said Roy Paxton Yih, President & CEO of Biocare. “The advanced Del-TECT™ PTEN and TMP/ERG probe technologies solidify Biocare’s position as the innovation leader in solid tissue prostate markers that began with the release of our groundbreaking PIN-4™ [CK5/14 + P63 + P504S] Multiplex immunohistochemistry [IHC] technology.” The high caliber CymoGen Dx team are “…very excited to now be a part of this innovative company and believe the efforts of our combined teams will bring added value for our customers”.

About CymoGen Dx
CymoGen Dx, named for its mission to provide state-of-the-art cytomolecular genetics diagnostic research products, is a national provider of advanced tools for identifying genomic aberrations in cancer cells found in tissue and bone marrow specimens. The products include unique 4 color FISH probes utilizing “Deletion Detection Probe” technology (Del-TECT™) that allow for greater accuracy in detecting genomic changes than ever before with enhanced accuracy in paraffin-embedded tissues common to pathology and pharmaceutical research.

About Biocare Medical
Biocare Medical, LLC is an innovator in developing and supplying world class automated immunohistochemistry (IHC) instrumentation and the full range of reagents for IHC and ISH lab testing. Biocare Medical is the market leader in simultaneous Multiplex IHC and antibody development, which aids in the assessment of clinical cases and accelerates turnaround time. The company’s customers include clinical histology laboratories, pharmaceutical companies, CROs, and biotechnology companies as well as academic, government, military, and other non-profit laboratories. Biocare Medical offers an expanding portfolio of integrated products to address the rapidly growing cancer and infectious disease diagnostic and research markets using tissue immunostaining and in situ hybridization methods. Biocare Medical is headquartered and has manufacturing facilities in Concord, California, and has a global distribution network. For more information, please visit www.biocare.net.